TiGenix NV , an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platform of allogeneic stem cells, announced today that it has received positive feedback from the U.S. Food and Drug Administration on an improved protocol for its global Phase III trial for the treatment of complex perianal fistulas in Crohn’s disease patients.